1.Prediction of thermal environment via revision of PMV index with body temperature
Yan MAO ; Jiaping LIU ; Hideki KUBOTA
Journal of Pharmaceutical Analysis 2007;19(1):60-62,80
PMV (Predicted Mean Vote) is a widely used index for evaluating the thermal environment. However, few studies have been conducted to take physiological values directly as evaluating indices. This paper assumes a linear relation between body temperature and both sweating rate and heat produced by shivering, and introduces the linear relation into the human heat balance equation to revise the classic PMV. And the assumption of linear relation is subsequently proved. The revised PMV possesses the same characteristic of dependent heat load as that of the classic one, and moreover it is convenient to be calculated.
2.Voluntary Gait Training for Complete Quadri/Paraplegia Patients Due to Chronic Spinal Cord Injury:T-HAL Method(Hetrotopic Triggered HAL Method)
Yukiyo SHIMIZU ; Hideki KADONE ; Shigeki KUBOTA ; Tetsuya ABE ; Tomoyuki UENO ; Yasushi HADA ; Masashi YAMAZAKI
The Japanese Journal of Rehabilitation Medicine 2019;56(7):560-564
3.Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
Hiroki Kubota ; Katsuhiro Fukuta ; Kenji Yamada ; Masahito Hirose ; Hiromichi Naruyama ; Yoshimasa Yanai ; Yasuyuki Yamada ; Hideki Watase ; Noriyasu Kawai ; Keiichi Tozawa ; Takahiro Yasui
Journal of Rural Medicine 2017;12(2):112-119
Objectives: To evaluate the efficacy of tegafur–uracil (UFT), a prodrug of 5-fluorouracil, plus cisplatin and dexamethasone in patients with docetaxel-refractory prostate cancers.
Methods: Twenty-five patients with docetaxel-refractory prostate cancer were administered oral UFT plus intravenous cisplatin (UFT-P therapy) and dexamethasone. Treatment responses were assessed monthly via prostate-specific antigen (PSA) level measurements. Treatment-related adverse events and overall survival were also assessed.
Results: UFT-P therapy resulted in decreased PSA levels in 14 (56%) patients and increased PSA levels in 11 (44%). In patients with increased PSA levels, 7 (64%) of the 11 patients displayed decreased PSA doubling times. The UFT-P therapy response rate was 84% (21/25 patients). Imaging studies revealed that tumor shrinkage during UFT-P therapy occurred in 1 patient in whom bilateral hydronephrosis caused by lymph node metastasis improved. The median survival time from docetaxel initiation was 36 months. In UFT-P-treated patients, the median PSA progression and overall survival times were 6 and 14 months, respectively. UFT-P treatment-related adverse events were mild diarrhea, general fatigue, and anorexia. Treatment was not discontinued for any of the patients. UFT-P therapy did not cause serious hepatic or renal dysfunction or pancytopenia.
Conclusions: UFT-P therapy is a safe and effective treatment for patients with docetaxel-refractory prostate cancer, although large-scale, multicenter, prospective studies are needed to validate these findings.
4.Existence of a Neuropathic Pain Component in Patients with Osteoarthritis of the Knee.
Seiji OHTORI ; Sumihisa ORITA ; Masaomi YAMASHITA ; Tetsuhiro ISHIKAWA ; Toshinori ITO ; Tomonori SHIGEMURA ; Hideki NISHIYAMA ; Shin KONNO ; Hideyuki OHTA ; Masashi TAKASO ; Gen INOUE ; Yawara EGUCHI ; Nobuyasu OCHIAI ; Shunji KISHIDA ; Kazuki KUNIYOSHI ; Yasuchika AOKI ; Gen ARAI ; Masayuki MIYAGI ; Hiroto KAMODA ; Miyako SUZKUKI ; Junichi NAKAMURA ; Takeo FURUYA ; Gou KUBOTA ; Yoshihiro SAKUMA ; Yasuhiro OIKAWA ; Masahiko SUZUKI ; Takahisa SASHO ; Koichi NAKAGAWA ; Tomoaki TOYONE ; Kazuhisa TAKAHASHI
Yonsei Medical Journal 2012;53(4):801-805
PURPOSE: Pain from osteoarthritis (OA) is generally classified as nociceptive (inflammatory). Animal models of knee OA have shown that sensory nerve fibers innervating the knee are significantly damaged with destruction of subchondral bone junction, and induce neuropathic pain (NP). Our objective was to examine NP in the knees of OA patients using painDETECT (an NP questionnaire) and to evaluate the relationship between NP, pain intensity, and stage of OA. MATERIALS AND METHODS: Ninety-two knee OA patients were evaluated in this study. Pain scores using Visual Analogue Scales (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), painDETECT, duration of symptoms, severity of OA using the Kellgren-Lawrence (KL) system, and amount of joint fluid were evaluated and compared using a Spearman's correlation coefficient by rank test. RESULTS: Our study identified at least 5.4% of our knee OA patients as likely to have NP and 15.2% as possibly having NP. The painDETECT score was significantly correlated with the VAS and WOMAC pain severity. Compared with the painDETECT score, there was a tendency for positive correlation with the KL grade, and tendency for negative correlation with the existence and amount of joint fluid, but these correlations were not significant. CONCLUSION: PainDETECT scores classified 5.4% of pain from knee OA as NP. NP tended to be seen in patients with less joint fluid and increased KL grade, both of which corresponded to late stages of OA. It is important to consider the existence of NP in the treatment of knee OA pain.
Aged
;
Aged, 80 and over
;
Female
;
Humans
;
Knee/pathology/physiopathology
;
Male
;
Middle Aged
;
Neuralgia/*physiopathology
;
Osteoarthritis, Knee/*physiopathology